adalimumab-bwwd 40 MG in 0.4 ML Prefilled Syringe

RxCUI: 2640425
RxNorm name: adalimumab-bwwd 40 MG in 0.4 ML Prefilled Syringe
Display name: adalimumab-bwwd 40 MG in 0.4 ML Prefilled Syringe
Full name: adalimumab-bwwd 40 MG in 0.4 ML Prefilled Syringe
Term type: PSN
Status: DailyMed mapping
Updated: 2026-06-04 23:38:56

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761059	Hadlima	adalimumab-bwwd	351(k) Interchangeable	Rx	2026-07-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Adalimumab-bwwd	ADALIMUMAB-BWWD	Cordavis Limited	c24655e5-796e-4127-b716-92f08d649c83	2025-10-17	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2640425

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 2 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
4774a951-3ce8-43b6-80b1-e6b23752aae6	adalimumab-bwwd 40 MG in 0.4 ML Prefilled Syringe [PSN] · 0.4 ML adalimumab-bwwd 100 MG/ML Prefilled Syringe [SCD] · adalimumab-bwwd 40 MG per 0.4 ML Prefilled Syringe [SY]	3	13	These highlights do not include all the information needed to use HADLIMA safely and effectively. See full prescribing information for HADLIMA. HADLIMA (adalimumab-bwwd) injection, for subcutaneous use Initial U.S. Approval: 2019 HADLIMA (adalimumab-bwwd) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee	20251017
c24655e5-796e-4127-b716-92f08d649c83	adalimumab-bwwd 40 MG in 0.4 ML Prefilled Syringe [PSN] · 0.4 ML adalimumab-bwwd 100 MG/ML Prefilled Syringe [SCD] · adalimumab-bwwd 40 MG per 0.4 ML Prefilled Syringe [SY]	3	2	These highlights do not include all the information needed to use ADALIMUMAB-BWWD safely and effectively. See full prescribing information for ADALIMUMAB-BWWD. ADALIMUMAB-BWWD injection, for subcutaneous use Initial U.S. Approval: 2019 Adalimumab-bwwd is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between th	20251017